TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer

[1]  V. Fedele,et al.  Permissive State of EMT: The Role of Immune Cell Compartment , 2020, Frontiers in Oncology.

[2]  A. Scarpa,et al.  From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer , 2020, Cells.

[3]  N. DeVito,et al.  Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion , 2019, Front. Immunol..

[4]  J. Tabernero,et al.  Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer , 2018, British Journal of Cancer.

[5]  Fenggui Wei,et al.  MicroRNA-10b mediates TGF-β1-regulated glioblastoma proliferation, migration and epithelial-mesenchymal transition. , 2017, International journal of oncology.

[6]  W. Yuan,et al.  Evaluation of Plasma MicroRNAs as Diagnostic and Prognostic Biomarkers in Pancreatic Adenocarcinoma: miR-196a and miR-210 Could Be Negative and Positive Prognostic Markers, Respectively , 2017, BioMed research international.

[7]  M. Korc,et al.  Erratum: microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions , 2014, Oncogene.

[8]  Zheng Li,et al.  miR-424-5p promotes proliferation of gastric cancer by targeting Smad3 through TGF-β signaling pathway , 2016, Oncotarget.

[9]  Single-stranded DNA binding protein Ssbp3 induces differentiation of mouse embryonic stem cells into trophoblast-like cells , 2016, Stem Cell Research & Therapy.

[10]  M. Levings,et al.  T regulatory cell chemokine production mediates pathogenic T cell attraction and suppression. , 2016, The Journal of clinical investigation.

[11]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[12]  M. Reni,et al.  CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Korc,et al.  Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes , 2015, Oncotarget.

[14]  X. Gou,et al.  Regulation of myofibroblast differentiation by miR-424 during epithelial-to-mesenchymal transition. , 2015, Archives of biochemistry and biophysics.

[15]  N. Tanaka,et al.  Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer , 2014, International journal of oncology.

[16]  W. Loh,et al.  A regression tree approach to identifying subgroups with differential treatment effects , 2014, Statistics in medicine.

[17]  J. Baselga,et al.  Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study , 2014, Cardiovascular Toxicology.

[18]  G. Kouraklis,et al.  Nuclear receptors in pancreatic tumor cells. , 2014, Anticancer research.

[19]  J. Baselga,et al.  First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma , 2014, Clinical Cancer Research.

[20]  N. Jamieson,et al.  IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival , 2014, Oncotarget.

[21]  A. Iavarone,et al.  The MicroRNA 424/503 Cluster Reduces CDC25A Expression during Cell Cycle Arrest Imposed by Transforming Growth Factor β in Mammary Epithelial Cells , 2014, Molecular and Cellular Biology.

[22]  R. Samant,et al.  Role of osteopontin in the pathophysiology of cancer. , 2014, Matrix biology : journal of the International Society for Matrix Biology.

[23]  Ivelina Gueorguieva,et al.  Defining a therapeutic window for the novel TGF-β inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. , 2014, British journal of clinical pharmacology.

[24]  R. Carlson,et al.  International adaptations of NCCN Clinical Practice Guidelines in Oncology. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[25]  Donghui Li,et al.  Biomarkers of TGF-β Signaling Pathway and Prognosis of Pancreatic Cancer , 2014, PloS one.

[26]  M. Korc,et al.  microRNA-10b enhances pancreatic cancer cell invasion by suppressing TIP30 expression and promoting EGF and TGF-β actions , 2013, Oncogene.

[27]  Jae-Bong Park,et al.  Small GTPase Rap1 regulates cell migration through regulation of small GTPase RhoA activity in response to transforming growth factor‐β1 , 2013, Journal of cellular physiology.

[28]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[29]  Kun Wang,et al.  The serum miR‐21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR‐21 expression confers chemoresistance by targeting FasL , 2013, Molecular oncology.

[30]  J. Tabernero,et al.  Phase Ib study evaluating safety and pharmacokinetics (PK) of the oral transforming growth factor-beta (TGF-ß) receptor I kinase inhibitor LY2157299 monohydrate (LY) when combined with gemcitabine in patients with advanced cancer. , 2013 .

[31]  Jian Li,et al.  MicroRNA-424-5p Suppresses the Expression of SOCS6 in Pancreatic Cancer , 2013, Pathology & Oncology Research.

[32]  Yin Lu,et al.  Identification and verification of transthyretin as a potential biomarker for pancreatic ductal adenocarcinoma , 2013, Journal of Cancer Research and Clinical Oncology.

[33]  Bo Wang,et al.  miR-148b Functions as a Tumor Suppressor in Pancreatic Cancer by Targeting AMPKα1 , 2012, Molecular Cancer Therapeutics.

[34]  Y. Oron,et al.  Knock‐down of plasminogen‐activator inhibitor‐1 enhances expression of E‐cadherin and promotes epithelial differentiation of human pancreatic adenocarcinoma cells , 2012, Journal of cellular physiology.

[35]  E. Van Cutsem,et al.  Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  Q. Yao,et al.  Overcoming drug resistance in pancreatic cancer , 2011, Expert opinion on therapeutic targets.

[37]  M. Korc,et al.  MicroRNA-10b Expression Correlates with Response to Neoadjuvant Therapy and Survival in Pancreatic Ductal Adenocarcinoma , 2011, Clinical Cancer Research.

[38]  D. Boyle,et al.  Platelet-derived growth factor and transforming growth factor beta synergistically potentiate inflammatory mediator synthesis by fibroblast-like synoviocytes , 2010, Arthritis research & therapy.

[39]  H. Taubert,et al.  Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival , 2010, International journal of cancer.

[40]  Damian McEntegart,et al.  Randomization by minimization for unbalanced treatment allocation , 2009, Statistics in medicine.

[41]  I. Türbachova,et al.  DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells , 2007, European journal of immunology.

[42]  B. Damaj,et al.  Expression and regulation of chemokine receptors in human natural killer cells. , 2001, Blood.

[43]  G. Capellá,et al.  Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells , 1998, Oncogene.

[44]  C. Haglund.  Tumour marker antigen CA 125 in pancreatic cancer : A comparison with CA 19-9 and CEA , 2007 .